The “real-world” effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study

INTRODUCTION: Omalizumab was proven to be effective and safe in patients with moderate-to-severe allergic asthma. However, there is no direct evidence of the benefits of add-on omalizumab in real-life practice in the Slovakian population. AIM: This subgroup analysis assessed the real-life effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Siracká, Simona, Tinková, Lenka Dzivá, Hochmuth, Luděk, Leščišinová, Helena, Hrubiško, Martin, Dostálová, Katarína, Jeseňák, Miloš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993205/
https://www.ncbi.nlm.nih.gov/pubmed/36909923
http://dx.doi.org/10.5114/ada.2022.116532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993205/
https://www.ncbi.nlm.nih.gov/pubmed/36909923
http://dx.doi.org/10.5114/ada.2022.116532

Ejemplares similares